Raymond Harris Archives
VUMC scientists discover key step to kidney fibrosis
Nov. 21, 2023—Researchers at Vanderbilt University Medical Center for the first time have shown that activation of the epidermal growth factor receptor (EGFR) is essential for the development of kidney fibrosis, tissue scarring following injury that can lead to kidney failure.
VUMC researchers upend dogma about vasopressin production
Jan. 5, 2023—Vanderbilt investigators have discovered that vasopressin, which has long been thought to be produced only in the brain, is also produced in the kidney.
Kidney diseases research collaboration renewed
Oct. 6, 2022—Vanderbilt University Medical Center and Bayer have agreed to continue a strategic research alliance to evaluate new drug candidates for the treatment of kidney diseases.
Inflammatory driver of obesity
Aug. 25, 2022—Blocking the EGF receptor signaling pathway in immune system macrophages represents a new target for improving insulin resistance in people with obesity.
Study sheds light on the dark side of obesity
May. 12, 2022—Vanderbilt research that promotes the anti-inflammatory pathway in macrophages could also reduce some of the bad side effects of obesity.
Gene expression in diabetic nephropathy
Aug. 5, 2021—Vanderbilt researchers are looking to mRNA populations in podocytes — kidney cells that help filter blood — to help identify potential targets for treating diabetic kidney disease.
Six Vanderbilt faculty elected as 2020 fellows of the AAAS
Dec. 3, 2020—Six Vanderbilt University faculty members have been elected 2020 fellows of the American Association for the Advancement of Science, an honor bestowed upon AAAS members by their peers.
Clue to diabetic kidney disease
Oct. 5, 2020—Vanderbilt researchers have identified a signaling pathway that promotes kidney fibrosis in patients with diabetes — and that could be targeted with an existing approved medication.
Sex differences in kidney injury
Jul. 25, 2019—Men are more susceptible to progressive kidney disease than women; new VUMC studies point to differences in the expression and activation of the EGF receptor.
Harris appointed co-chair of ASN’s Kidney Health Initiative
Dec. 20, 2018—Raymond Harris, MD, Ann and Roscoe R. Robinson Professor of Nephrology and director of the Vanderbilt Center for Kidney Disease, has been appointed co-chair of the American Society of Nephrology’s (ASN) Kidney Health Initiative (KHI).
Targeting diabetic kidney disease
Oct. 12, 2018—Pathways activated by the epidermal growth factor receptor may be attractive targets to treat diabetic kidney disease, according to new findings from Vanderbilt investigators.
YAP after acute kidney injury
Aug. 16, 2018—Activation of the signaling protein YAP may be a target for treating acute kidney injury, which affects up to 20 percent of hospitalized patients.
